Effective, Fast Treatment
When it comes to varicose veins, Varithena delivers results — improving symptoms, appearance and underlying GSV system incompetence.1
Including five of the most relevant varicose veins symptoms: heaviness, achiness, swelling, throbbing and itching
Improved vein appearance
In assessments by both patients and doctors
Reliability You Can Count On
Varithena is the only sclerosing agent specially formulated with patented technology to produce a uniform density, size and stability (UDSS™) microfoam that effectively displaces blood in the widest range of vessel shapes and sizes. This gentle, easy-to-deliver NTNT solution is designed to provide reliable results while reducing complications.
Hear from your peers. Read case study summaries describing patient histories, workups, Varithena treatment processes and outcomes.
Quick Treatment Delivery, Quick Results
Deliver NTNT Treatment Efficiently
Varithena procedures are designed to be straightforward and simple. You usually numb the injection site, but no additional anesthesia is required. It often takes less than an hour for the entire treatment session.
Lower the Need for Multiple Therapies
A retrospective claims database analysis shows that about 50% of patients seeking invasive treatment for varicose veins require re-treatment at least once for their condition. With Varithena, a single treatment session may be all that’s needed, depending on the number and size of veins to be treated.
Before & After Treatment Photos
These photos show results after one treatment with Varithena. Additional treatments may be needed, depending on the number and size of veins to be treated.
All images compare foams within approximately 10 seconds of creation. Photos of physician-compounded foam feature examples of manually created foam made 1:4 with 1% polidocanol solution and room air, Tessari technique. Because of varying conditions and techniques, properties of physician-compounded foams may vary. Photos by RSSL (Reading Scientific Services Ltd, UK).
A Closer Look at the Data
Varithena safety and efficacy have been evaluated in 1,333 patients in 12 clinical trials. Our two pivotal clinical trials demonstrate the efficacy and durability of Varithena treatment in the GSV.
Varithena Improves Symptoms
Improvement in symptoms as measured by change in VVSymQ® Score from baseline to week 8. A reduction in in VVSymQ® Score indicates an improvement in symptoms.
Varithena Improves Varicose Vein Appearance
Improvement in appearance as measured by change in IPR-V3 rating from baseline to Week 8. A reduction in IPR-V3 indicates an improvement in appearance. IPR-V3: independent photography review of visible varicose veins (physician assessment); physicians rated appearance of patients’ visible varicosities on a 5-point scale.
- Compared to FDA cleared or approved indications for other varicose vein therapies; CEAP Grade C2-6.
Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Important Safety Information
The use of Varithena® is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.Varithena® can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.Physicians administering Varithena® must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena®.
See Full Prescribing Information for Varithena®